Background: Dalbavancin is a long-half-life (9 -12 days) glycopeptide, now in Phase 3 development. Its pharmacokinetics may facilitate home intravenous therapy, early discharge and long prophylaxis.
Introduction
Dalbavancin is a new glycopeptide, now in Phase 3 development. Its most notable feature is a serum half-life of 9-12 days in healthy volunteers. 1 This may allow a weekly regimen, with early discharge of recovering patients. More controversially, these pharmacodynamics might be exploited to give prolonged prophylactic protection against Gram-positive infections. A recently published Phase 2 trial indicates a cure rate of 94% for a two-dose, once weekly, dalbavancin regimen in skin and skin structure infections. 2 Dalbavancin is active in broth at < _ 1 mg/L against virtually all staphylococci and streptococci: 3 vanA-positive enterococci are resistant but, as with teicoplanin, enterococci with other modes of inherent and acquired vancomycin resistance remain susceptible in vitro, presumably because dalbavancin does not act as an inducer. We characterized dalbavancin's activity in agar, using both the British Society for Antimicrobial Chemotherapy (BSAC) 4 and the National Committee for Clinical Laboratory Standards (NCCLS) methodology. 5 The test bacteria were staphylococci and 'viridans' a-and non-haemolytic streptococci selected for multi-resistance and epidemiological diversity. , Streptococcus mitis (6), Streptococcus salivarius (4), Streptococcus gordonii (4) and Streptococcus sanguis group (3). All the organisms were recent clinical isolates from patients in the UK. Agar dilution MIC determinations followed the standard methods of the BSAC 4 and NCCLS. 5 Salient differences are that the BSAC uses Iso-Sensitest agar, supplemented with 5% defibrinated equine blood for streptococci only, and with plates incubated in air for 18 -20 h at 378C, whereas the NCCLS uses MuellerHinton agar, supplemented with 5% ovine blood for streptococci, and incubated in air for 16 -20 h at 358C. The BSAC replaces IsoSensitest agar with Columbia agar + 2% NaCl incubated at 308C for the detection of methicillin-resistant staphylococci, with incubation extended up to 48 h for coagulase-negative species; the NCCLS uses Mueller -Hinton agar with 2% NaCl, incubated at 358C. Agars were obtained from Oxoid (Basingstoke, Hampshire, UK), equine blood from E&O Laboratories (Bonnybridge, Scotland, UK) and ovine blood from TCS (Buckingham, Buckinghamshire, UK). Antibiotic reference powders were sourced as follows: dalbavancin (Vicuron, King of Prussia, PA, USA); teicoplanin and quinupristin/dalfopristin (Aventis, West Malling, Kent, UK); linezolid (Pharmacia, Milton Keynes, Buckinghamshire, UK); cefazolin, erythromycin, gentamicin, oxacillin, penicillin, rifampicin, tetracycline and vancomycin (Sigma, Poole, Dorset, UK). Breakpoints were those advocated by the NCCLS and BSAC for their respective methods. 4 ,5 
Materials and methods

Results and discussion
MIC distributions for dalbavancin and its comparator glycopeptides by the two methods are show in Table 1 . Cross-agreement data are illustrated, in full, for dalbavancin only, in Table 2 ; agreement data for the comparator drugs are summarized in Table 3 . All the glycopeptide MIC distributions were unimodal andexcept in the case of teicoplanin against staphylococci-were very tightly clustered, with >90% of values falling within four doubling dilutions or fewer. In view of these distributions, both the mode and geometric mean MICs (Table 1) are useful summary parameters. Dalbavancin MIC values by the NCCLS method were equal to those by the BSAC method or, for about half the isolates, were one dilution higher (Tables 1 and 2) , with this latter trend most obvious in the higher geometric mean values. Only in four cases (one S. aureus and three viridans streptococci) were the dalbavancin MICs by the two methods more than one dilution apart and, even here, the discrepancy was only two dilutions ( Table 2 ). Teicoplanin MICs for S. aureus also tended to be slightly higher by NCCLS methodology, whereas no such trend was seen for teicoplanin with other species groups; for vancomycin there was no trend for either method to give higher values (Table 1) .
Among the comparator drugs there was also generally good agreement between the two methods, both as regards measured MICs and susceptibility categorizations ( Table 3 ). The exceptions were: (i) the NCCLS method, which, with its low oxacillin breakpoints for CoNS, counted more (58/92 versus 44/92) of these organisms as resistant than did the BSAC method; (ii) the NCCLS method, by virtue of a higher breakpoint, counted fewer viridans streptococci as tetracycline resistant; (iii) the BSAC method (that does not have an intermediate category for these combinations) scored many of the streptococci as resistant to penicillin, whereas they were intermediate by the NCCLS criteria; and (iv) some CoNS found gentamicin resistant by BSAC methodology were graded as intermediate or susceptible by NCCLS methodology.
Six S. aureus and 23 CoNS were resistant or intermediate to teicoplanin based on either or both the BSAC and NCCLS criteria. For all of these organisms the dalbavancin MICs were < _ 2 mg/L by both methods, and vancomycin MICs were < _ 4 mg/L. MICs for the most teicoplanin-resistant S. aureus and CoNS isolates are shown in Table 4 . More generally, the geometric mean dalbavancin MIC was 0.31 mg/L for 23 CoNS staphylococci with teicoplanin MICs >4 mg/L (BSAC method), compared with 0.18 mg/L for 69 with teicoplanin MICs < _ 4 mg/L. Corresponding values for vancomycin were 1.94 and 1.38 mg/L, respectively. Thus, dalbavancin, like vancomycin, retained good activity against the teicoplanin-non-susceptible organisms, although these were not as susceptible as those that were teicoplanin-susceptible.
These studies show that, for staphylococci and viridans streptococci-which are the major Gram-positive pathogens in, for example, neutropenic fevers 6 -dalbavancin had good activity, better than vancomycin and teicoplanin, irrespective of whether this activity was measured by BSAC or NCCLS methods. The MIC values recorded here, by agar dilution methods, are slightly higher than those found elsewhere by the NCCLS broth microdilution method, 3 but remain very low in comparison with the serum levels, where a 1 g loading dose (as used in Phase 2 trials) gave a C max of 312 mg/L, with the serum level still >20 mg/L even 1 week later. 
